In many phase III trials for age-related macular degeneration, retinal vein occlusion, and diabetic macular edema [13,14,15,16,17], central macular thickness (CMT) values have been used as the criteria for the administration of anti-VEGF therapy to provide quantifiable criteria for treatment. The gene discussed is VEGFA; the disease is retinal vein occlusion.